TRC-logo
  • Library of symbols
    • Arrows
    • Molecular Symbols
    • Drug Targets (Receptors, channels, etc)
    • Cells And Organelles
    • Organs
    • Organs2
    • Tissue And Cell Types
    • Blood and Immune system related cells
    • Populations
    • Pathophysiology
    • Medication And Other Items
    • Miscellaneous
    • Vb graph TRC style
    • Compositions
  • Pharmacodynamics
    • Ligands
      • Chemical interactions
    • Targets
      • Receptors
        • G-protein coupled receptors
          • G-protein cycle
            • Gi-protein coupled
            • Gq-coupled protein
            • Gs-coupled protein
        • Nuclear receptor
          • Steroid receptors
          • Non-steroid receptor
        • Ligand-gated ion channel
        • Kinase receptor
      • Enzymes
      • Transport proteins
    • Ligand and receptor interactions
      • Binding
        • Occupancy
        • Affinity
        • Reversible versus irreversible binding
        • Stereospecificity
          • Stereospecificity (2)
      • From binding to response
        • Dose-response curves
        • Efficacy
        • Potency
        • Tissue response
          • More ligands at the receptor
            • Competitive antagonism
            • Non-competitive antagonism
            • Partial agonism
            • Inverse agonism
              • Inverse agonism (2)
            • Different ligands
            • Biased Agonism
        • Selectivity
          • Therapeutic index
      • Regulation of response
        • Tachyphylaxis
          • Down-regulation
          • Receptor desensitisation
        • Supersensitivity
          • Up-regulation
    • Signalling: systems and concepts
      • Autonomic nervous system
        • Sympathetic vs. parasympathetic
          • Combined innervation (1)
          • Combined innervation (2)
        • Receptor diversity (1)
        • Receptor diversity (2)
        • Post vs. presynaptic receptors (1)
        • Post vs. presynaptic receptors (2)
        • Reuptake transporters
          • Reuptake transporters - noradrenalin
        • Potencies at receptors
        • Drug selectivity
        • Receptor localisation - Alpha receptors
        • Receptor localisation - Beta receptors
      • Inflammatory system
        • Glucocorticoids in the immune response
          • Glucocorticosteroid effects
          • Ligand directed signalling
        • Prostaglandin synthesis
        • Leukotriene synthesis
  • Pharmacokinetics
    • Therapeutic drug concentrations
    • Routes of administration
      • Intravenous administration
      • Drug Absorption (extravascular)
        • Bioavailability
        • P-glycoprotein
        • Oral administration
          • Drug absorption from intestine
          • First-pass effect
          • Factors influencing absorption
          • Sustained release
        • Transdermal absorption
    • Drug Distribution
      • Volume of distribution
      • Tissue distribution
        • Tissue distribution (2)
        • Tissue distribution (3)
        • Changes in distribution
      • Transport over barriers
        • Blood brain barrier
      • Protein binding
        • Protein binding (2)
    • Drug elimination
      • Clearance
        • Dose and AUC
          • Elimination rate constant
          • Effect on half-life
      • Drug regimen determination
        • Intravenous single dosing
        • Oral single dosing
        • Intravenous infusion
          • Steady state
        • Loading dosing
        • Multiple oral dosing
      • Excretion
        • Renal excretion
          • Glomerular filtration
          • Tubular secretion
          • Tubular reabsorption
        • Creatinine clearance
      • Metabolism
        • Biotransformation
        • Phase I and phase II
        • CYP enzymes
          • Induction
          • Inhibition
        • Effect on first-pass
        • Factors influencing metabolism
          • Pharmacogenetics
        • Phenoconversion
        • Biliary excretion
  • Adverse Drug Reactions
    • Classification of adverse drug reactions
    • Mechanisms of toxicity
      • Immune-mediated mechanisms
      • Enzyme and receptor-mediated mechanisms
      • Cellular repair mechanisms and cell death
      • Organ directed toxicity
      • Drug-induced carcinogenesis
      • Drug-induced teratogenesis
    • Management of ADRs
  • Acute medicine
    • Pathophysiology of shock
    • Theory of shock
      • Treatment of shock
        • Fluids
        • Norepinephrine in shock
        • Dopamine in shock
        • Dobutamine in shock
        • Isoprenaline in shock
        • Atropine in shock
    • Cerebral oedema
      • BBB in cerebral oedema
        • Mannitol
        • Dexamethasone
  • Cardiology
    • Cardiac muscle electrophysiology
      • ECG, pressure and volume
      • Myocyte
    • Cardiac function
      • Cardiac output
        • Preload
        • Afterload
      • Frank-Starling mechanism
      • Heart failure
        • Neurohumoral compensation
          • Remodelling
        • Treatment of heart failure
          • Diuretics in CHF
          • Spironolactone in CHF
          • ACE inhibitors
          • Angiotensin II antagonists
          • Beta-blockers in CHF
          • Cardiac glycosides
    • Innervation of the heart
      • Arrhythmias
        • Antiarrhythmic treatment
          • Class I drugs
          • Class II drugs
          • Class III drugs
          • Class IV drugs
    • Oxygen in the myocardium
      • Angina pectoris
        • Vascular NO system
          • Nitrates
        • Beta-blockers in cardio
        • Calcium channel blockers
        • ACE inhibitors
        • Ivabradine
    • Blood pressure control
      • Renin-angiotensin-aldosterone system
        • Regulation by aldosterone in cardio
      • Hypertension
        • Treatment of hypertension
          • Beta-blockers in cardio
          • Calcium channel blockers
          • Diuretics in cardio
          • Spironolactone in cardio
          • ACE inhibitors
          • Angiotensin II antagonists
          • Renin inhibitors
          • Alpha-blockers in cardio
          • Centrally acting antihypertensives
          • Direct vasodilators
  • Endocrinology & metabolism
    • Pituitary
      • Panhypopituitarism
        • Thyroxine
        • Glucocorticoids in endocrinology
        • Growth hormone
        • Androgens
        • Estrogens
      • Acromegaly
        • Dopamine agonists
        • Somatostatin
        • GH antagonists
      • Pathological hyperprolactinemia
        • Dopamine agonists
      • Diabetes insipidus
        • Vasopressin
    • Hypothalamic-pituitary-thyroid axis
      • Hypothalamic TRH cell
      • Pituitary TSH cell
      • Synthesis of thyroid hormone
      • TSH control
        • Hyperthyroidism
          • Thionamides
        • Hypothyroidism
          • Thyroxine
    • Hypothalamic-pituitary-adrenal axis
      • Cushing's disease
        • Adrenal cortex cell
        • Cushing's syndrome
          • Metyrapone
          • Ketoconazole
      • Secondary adrenal insufficiency
        • Glucocorticoids in endocrinology
      • Primary adrenal insufficiency
        • Glucocorticoids in endocrinology
        • Mineralocorticoids
    • Hypothalamic-pituitary-gonadal axis
      • Hypogonadism
        • Estrogens
        • Androgens
      • Regulation of the ovary (1)
      • Regulation of the ovary (2)
        • Post menopause
          • Estrogens
      • Regulation of the testis
    • Circulatory volume regulation
      • Hyperaldosteronism
        • Spironolactone in endo
    • Stress response
      • Pheochromocytoma
        • Alpha1-blockers in endocrinology
        • Beta-blockers in endocrinology
    • Glucose metabolism
      • Diabetes mellitus type I
        • Insulin
      • Diabetes mellitus type II
        • Sulphonylureas
        • Biguanides
        • Alpha-glucosidase inhibitors
        • Thiazolidinediones
        • Incretin mimetics
        • Dipeptidyl peptidase 4 inhibitors
        • Insulin
      • Hypoglycemia
        • Glucagon
    • Calcium metabolism
      • Hyperparathyroidism
        • Bisphosphonates in hyperparathyroidism
      • Hypoparathyroidism
        • Vitamin D analogues
        • Calcium
    • Blood lipoproteins
      • Lipid absorption
      • Endogenous lipid transport
        • LDL-R cycle
      • Lipoproteins and the hepatocyte
        • Hyperlipidemia
        • Atherosclerosis
          • Treatment of hyperlipidemia
            • Statins
            • Fibric acid derivatives
            • Bile acid resins
            • Nicotinic acid
            • Fish oils
            • Ezetimibe
  • Gastroenterology
    • GI anatomy
      • GI motility control
        • Intrinsic nervous system
      • Constipation
        • Fibre
        • Osmotic laxatives
        • Stimulant laxatives
        • Stool softeners
      • Constipation in elderly
        • Drug-induced constipation
          • Treatment of constipation
        • Faecal incontinence
          • Treatment of faecal incontinence
      • Diarrhoea
        • Opiate receptors in GI
          • Opiate agonists in GI
    • Nausea/vomiting
      • Anti-emetics
      • D2 antagonists in GI
      • 5-HT3 antagonists
      • Antihistamines in GI
      • Dexamethasone in emesis
      • Neurokinin-1 antagonists
      • Cholinergic drugs in GI
      • Erythromycin in GI
    • Peptic ulcer
      • Bismuth compounds
      • H. pylori treatment
      • Systemic gastric acid control
        • Food effects on gastric acid control
        • Parietal cell
          • Antacids for ulcers
          • H2 antagonists for ulcers
          • Proton pump inhibitors for ulcers
          • Prostaglandins
          • Mucosa protectives
    • Reflux disease
      • Antacids for reflux
      • H2-antagonists for reflux
      • Proton pump inhibitors for reflux
      • Mucosa protectives
      • 5-HT4 agonists
    • Liver & portal vasculature
      • Liver failure
        • Portal hypertension
          • Treatment of oesophageal varices
        • Ascites
          • Treatment of ascites
        • Encephalopathy
          • Treatment of encephalopathy
      • Hepatitis
        • Interferons
        • NRTI for hepatitis B
        • Ribavirin for hepC
    • Inflammatory Bowel Disease (IBD)
      • IBD part 2
        • Salicylates in IBD
        • Glucocorticoids in IBD
        • Methotrexate in IBD
        • Azathioprine in IBD
        • anti-TNF for IBD
    • Gallbladder
      • Cholelithiasis
        • Cholecystectomy
        • Bile salts
    • Pancreas
      • Pancreatitis
        • Pancreatic enzymes
  • Gynaecology & obstetrics
    • Male reproduction
      • Male hypgonadism
        • Treatment of hypogonadism (m)
      • Erectile dysfunction
        • Sildenafil
    • Female reproduction
      • Ovarian follicle
        • Contraception
        • Morning after pill
      • Female hypogonadism
        • Treatment of hypogonadism (m)
        • Fertility treatment
      • Menopausal symptoms
        • HRT
      • Postmenopausal osteoporosis
        • Bisphosphonates
        • SERMs
      • Fluor vaginalis
        • Antimycotics
    • Pregnancy
      • Hypertension in pregnancy
        • Methyldopa
        • Ketanserin
        • Nifedipine
        • Hydralazine
      • (Pre) eclampsia
        • Magnesium sulphate
        • Nifedipine
      • Delivery
      • Preterm labour
        • Beta2-agonists in pregnancy
        • Indomethacin
        • Atosiban
        • Nifedipine
      • Abortion
        • Mifepristone-misoprostol
      • Induction of labour
        • Oxytocin
        • Prostaglandins in pregnancy
  • Haematology
    • Thrombosis
      • Platelet aggregation
        • Aspirin in haemostasis
        • Platelet aggregation inhibitors
      • Coagulation
        • Coagulation cascade
      • Anticoagulation
        • Anticoagulation drugs
        • Heparin
        • Vitamin K antagonists
        • Direct thrombin inhibitors
        • Direct factor Xa inhibitors
      • Fibrinolysis
        • Thrombolytics
        • Antifibrinolytics
        • Tranexaminic acid
    • Iron deficiency anemia
      • Iron supplementation
  • Immunology
    • Allergic rhinitis
      • Antihistamines for allergic rhinitis
      • Cromolyn sodium
      • Corticosteroids for allergic rhinitis
    • Dermatitis
      • Topical agents for dematitis
      • Corticosteroids for dermatitis
      • Antihistamines for dermatitis
    • SLE
      • Immunology of SLE
        • Corticosteroids for SLE
          • Corticosteroids and therapy
        • Azathioprine/MMF for SLE
        • Antimalarials for SLE
        • Alkylating agents for SLE
    • Transplantation
      • A/B/O system in transplant
      • HLA matching
        • Immunosuppressive agents
          • IL-2 receptor antagonists
          • Anti-thymocyte globulin
          • Anti-CD3
          • Inhibitor T-cell activation in transplant
          • Calcineurin inhibitors
          • Non-calcineurin agents
          • Corticosteroids in transplant
          • Azathioprine/MMF in transplant
          • Cyclophosphamide in transplant
    • Vaccination
      • TI-1 antigens
      • TI-2 antigens
      • TH1-cell dependent response
      • TH2-cell dependent response
  • Infectious diseases
    • Bacteria
      • Gram-positive/negative
      • Cell wall synthesis
        • β-lactams: penicillins
        • β-lactams: cephalosporins
        • Glycopeptides
        • Isoniazid
        • Daptomycin
      • Folate synthesis
        • Sulfonamides
        • Trimethoprim
      • Bacterial protein synthesis
        • Aminoglycosides
        • Tetracyclines
        • Macrolides
        • Retapamulin
      • RNA synthesis
        • Rifampicin
      • Bacterial DNA
        • Quinolones
        • Nitrofurantoin
        • Metronidazole
    • Viruses
      • Retrovirus
        • NRTI
        • NNRTI
        • Protease inhibitors
        • Maraviroc
        • Raltegravir
      • Influenza virus
        • Amantadine
        • Neuraminidase inhibitors
      • Herpes virus
        • Acyclovir
      • Hepatitis virus
        • Interferons
    • Fungi
      • Azoles
      • Polyenes
    • Worms
      • Microtubule synthesis inhibitors
      • Paralyzers
    • Protozoa
      • Malaria cycle
        • Aminoquinolones
        • Folate synthesis inhibitors
        • Nitroimidazoles
  • Musculoskeletal system
    • Synovial joint
      • Rheumatoid arthritis
        • Therapy of RA
      • Multiple hit model
        • NSAIDs for RA
        • COX-2 inhibitors
        • Methotrexate in RA
        • Leflunomide
        • Abatacept
        • Rituximab
        • Tocilizumab
      • Cytokines in RA
        • TNFα blocking agents
      • Gout
        • Colchicine
        • Xanthine oxidase inhibitors
        • Uricosurics
  • Nephrology & Urology
    • Renal function
      • Proximal tubule
        • Osmotic diuretics
      • Loop of Henle
        • Loop diuretics
      • Distal tubule
        • Thiazide diuretics
      • Collecting duct
        • Potassium-sparing diuretics
      • Regulation by aldosterone in cardio
        • Spironolactone in renal
    • Acute renal failure
      • Treatment of ARF
    • Chronic kidney disease
      • RAAS
        • Treatment of CKD
      • Renal anemia
        • EPO
      • Metabolic acidosis
      • Mineral and bone disease
      • Vitamin D deficiency
      • Secondary hyperparathyroidism
    • (In)continence
      • Bladder and incontinence
      • Micturition reflex
        • Urge incontinence
          • Parasympathicolytics
          • Alpha-receptor agonists in urology
        • Stress incontinence
        • Drug induced incontinence
        • Urinary retention
        • Prostate hyperplasia
          • Alpha1-receptor blockers in urology
          • Finasteride
  • Neurology
    • Action potential
      • Action potential 2
        • Action potential 3
          • Action potential 4
    • Synapse
      • Cholinergic synapse
        • Myasthenia gravis
    • Neuronal network
      • Dopamine network
        • Parkinsons
    • Temperature regulation
      • Neuronal control
        • Hypothermia
        • Hyperthermia
        • Fever
          • Mechanism of fever
          • NSAIDs for fever
          • Paracetamol for fever
        • Body temperature and fever
      • Endocrine control
    • Pain
      • Pain pathway
      • Peripheral stimulation
        • Prostaglandin synthesis
          • NSAIDs in pain
          • COX-2 inhibitors
          • Paracetamol for pain
      • Gate control / dorsal horn
        • TENS
        • Local anaesthetics
        • Ziconotide
      • Central modulation
        • Opioids
        • Paracetamol for pain
      • Pain control
        • Adjunct pain treatment
    • Confusion
      • Drug-induced delirium
        • Anticholinergic side effects
      • Alzheimers disease
        • AChE inhibitors
        • NMDA antagonists
        • Antioxidants
      • Lewy body dementia
    • Epilepsy
      • Cellular control
        • Cellular dysregulation
      • Neuronal network control
        • Neuronal network dysregulation
      • Generalised seizures
        • Antiepileptic drugs
          • GABA potentiators
          • Sodium channel inhibitors
          • Valproic acid
      • Absences
        • Ethosuximide
  • Ophthalmology
    • Anatomy of the eye
    • Control of pupil size
      • Mydriatics (muscarinic antagonists)
      • Mydriatics (alpha agonists)
    • Production of aqueous humor
      • Glaucoma
        • Beta-blockers in glaucoma
        • Alpha-agonists for glaucoma
        • Carbonic anhydrase inhibitors in glaucoma
        • Parasympathomimetics in glaucoma
        • Prostaglandin agonists in glaucoma
    • Age-related macular degeneration
      • Treatment of AMD
    • Ocular infections
      • Antimicrobials for ocular infections
      • Glucocorticoids for eye
    • Allergic conjunctivitis
      • Mast cell stabilizers for the eye
      • Histamine antagonists for the eye
    • Corpus alienum in the eye
      • Local anaesthetics in the eye
  • Oncology
    • Normal cells
    • Cancer cells
      • Treatment of tumors
        • Cell cycle and cytostatics
          • Alkylating cytostatics
          • Trabectedin
          • Antimetabolites
          • Antimitotics
          • Strand-breakage agents
          • Cytotoxic drug-induced emesis
          • Treatment of emesis
        • Tumors and hormones
          • Antihormones (1)
            • Antihormones (2)
          • Aromatase inhibitors (1)
            • Aromatase inhibitors (2)
          • Progestagens (1)
            • Progestagens (2)
          • LHRH-analogues
        • Antibody treatment
          • Trastuzumab
          • Cetuximab
          • Bevacizumab
          • Panitumumab
        • Protein kinase inhibitors
          • Imatinib
          • Erlotinib
          • Sunitinib / sorafenib
          • mTOR inhibitors
      • Rational drug design
      • Palliative therapy
        • Bisphosphonates in oncology
        • Denosumab
  • Psychiatry
    • Neuronal synapse
      • Synaptic receptors
        • Post-synaptic response
      • ACH brain
        • ACH neurons
      • GABA brain
        • GABA neurons
      • DA brain
        • DA neurons
      • NE brain
        • NE neurons
      • 5-HT brain
        • 5-HT neurons
      • CB Brain
        • CB neurons
      • Histamine brain
        • Histamine neurons
      • Glutamate brain
        • Glutamate neurons
    • Stress-body and brain
      • Cortisol and depression
        • 5-HT neurons & steroids
    • Depression
      • Antidepressant delayed response
        • SSRIs
        • Tricyclics
        • Mirtazapine
        • MAOIs
    • Anxiety
      • Anxiety (2)
        • Treatment of anxiety
          • Benzodiazepines
            • GABA-A receptors
          • Beta-blockers in psychiatry
          • SSRIs for anxiety
    • Bipolar disorder
      • Lithium
      • Mood stabilizers
    • Schizophrenia
      • Schizophrenia - mesolimbic
        • Dopamine 2 antagonists
          • High potency antipsychotics
          • Atypical antipsychotics
      • Schizophrenia - mesocortical
      • Schizophrenia - nigrostriatal
        • Acute dystonia
          • Anticholinergics for acute dystonia
        • Akathisia
          • Beta-blockers for akathisia
        • Pseudoparkinsonism
          • Anticholinergics for pseudoparkinsonism
        • Tardive dyskinesia
      • Schizophrenia - tuberoinfundibular
  • Pulmonology
    • Normal bronchiolus
    • Inflammation
      • Inflammatory process
        • Beta2-receptor effects in lung
        • Nedocromil effects
        • Corticosteroid effects
        • Leukotriene modifying effects
    • Lung cancer
      • Treatment of lung cancer
      • Treatment of NSCLC
        • Response rate
      • Treatment of SCLC
    • Constriction
      • Beta effect in lung
        • Beta-agonists for asthma
      • Anticholinergic effect in lung
        • Anticholinergics for lung
      • Theophylline
    • Allergic asthma
      • Antigen trigger
        • Histamine
          • Antihistamines
          • Nedocromil
        • Leukotriene release
          • Leukotriene modifiers
        • Late inflammatory mediators
          • Corticosteroids
        • Omalizumab
    • Pulmonary circulation
    • Pulmonary hypertension
      • Lung capillary
        • PH pathophysiology
          • Treatment of PH
          • Prostacyclins in PH
          • Sildenafil in PH
          • ET-R antagonists
    • Mucus hypersecretion
      • Mucolytic agents
      • Mucus & Anticholinergic agents
        • Anticholinergics for mucus
      • Mucus & antibiotics
        • Antibiotics
    • Alveolar anatomy
      • Alveolar damage
        • Alpha-1 antitrypsin
    • Sarcoidosis
      • Pathophysiology of sarcoidosis
        • Treatment of sarcoidosis
    • Pulmonary fibrosis
      • Pathophysiology of fibrosis
        • Treatment of fibrosis
  • Pediatrics
    • Absorption in pediatrics
    • Distribution in pediatrics
      • Blood brain barrier
      • Protein binding in pediatrics
    • Metabolism in pediatrics
      • Half-life in pediatrics
    • Excretion in pediatrics
    • Dosage in pediatrics
  • Geriatrics
    • Pharmacokinetics in elderly
      • Absorption in elderly
      • Distribution in elderly
      • Metabolism in elderly
      • Excretion in elderly
    • Drug interactions
      • Pharmacokinetic interactions
      • Pharmacodynamic interactions
      • Adverse effects
        • Falls
        • Double incontinence
      • Toxicity in elderly
      • Compliance in elderly
      • Therapy regimen
  • New mechanisms
    • Varenicline
    • Deferasirox
    • Rilonacept
    • Vernakalant
    • Lomitapide
    • Mirabegron
    • Rimonabant
    • Nitisinone
    • Eculizumab
    • Icatibant
    • Sapropterin
    • Ustekinumab
    • Romiplostim
    • Tolvaptan
  • Pregnancy & Teratogenicity
    • Drugs in pregnancy
      • Distribution in pregnancy
      • Absorption in pregnancy
      • Clearance in pregnancy
        • Metabolism in pregnancy
        • Excretion in pregnancy
    • Teratogenicity
      • Factors in fetal drug exposure
      • Teratogenic effects
      • Classification of teratogens
        • Treatment of a pregnant patient
New mechanisms
Vernakalant
last updated 08-05-2025

You may also like

topic img
New mechanisms
<p>X</p>
topic img
Varenicline
topic img
Deferasirox
Search

Make a TRC selection

use these filters to get what you're looking for. Afterwards, these selections stays active

Show results

Share this data

Please use this data everywhere. In E-learnings, presentations or studies.

Embed this content on you website, your E-learning platform or on your intranet.

We keep this data up to date and scientifically correct.

What would you like to embed?

Save this image to my computer
Download a PowerPoint file with aspect ratio 4:3
Download a PowerPoint file with aspect ratio 16:9
Download a PowerPoint file with aspect ratio 16:10

Download Word file (with links)
Download Word file (without links)
Embed on your website

hoi

Copy to clipboard
Comments on this page? Please email: trc@chdr.nl
Disclaimer
CHDR-logo
About this site, disclaimer and Terms of Use

Welcome to the website of the TRC Pharmacology Database. The information provided on this site is for general informational and educational purposes only. Please read and review these Terms of Use carefully before accessing or using this website. By accessing or using this site, you acknowledge that you have read, understood and agreed to the Terms of Use Agreement. If you do not agree to the Terms of Use, you may not access or use the site.

The Teaching Resource Centre (TRC) Pharmacology Database is a teaching website for a better understanding of drug mechanisms, primarily focussing on (bio)medical or students Biopharmaceutical Sciences. The TRC is a product of the Centre for Human Drug Research (CHDR), established in collaboration with primarily the Leiden University Medical Centre (LUMC).


Copyright information

We are striving to make the TRC Pharmacology Database the best resource for pharmacology teaching to medical students on the World Wide Web. We use multiple sources of data in our work and a large part of this information is checked and edited by our staff and clinical experts.


Copyright Status

Information available from this site (graphics, animations, graphs, texts, questions, cases and other reference data) is within the public domain. Public domain information on TRC Pharmacology Database Web pages may be freely copied for individual use only. However, it is requested that in any subsequent use of this work, TRC be given appropriate acknowledgment. The user hereby agrees that he/she may not distribute copies of TRC material to other person or persons, without explicit approval of the TRC Editorial board.


Disclaimer

All content on this website, including graphics, animations, graphs, texts, questions, cases and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical professional. The TRC staff will use reasonable efforts to include reliable, up to date, and accurate information on the website, but makes no warranties or representations of any kind as to its accuracy, currency or completeness. You agree that access to and use of this website and the content thereof is at your own risk. Neither TRC nor any party involved in creating, producing or delivering this website shall be liable for any damages, including without limitation, direct, incidental, consequential, indirect or punitive damages, arising out of access to, use of or inability to use this website, or any errors or omissions in the content thereof. This limitation includes damages to, or for any viruses that infect your computer equipment.


By printing, downloading, or using the content on TRC Pharmacology Database you agree to our full terms.


Liability: For information available from this server, the Leiden University Medical Centre and the Center for Human Drug Research do not warrant or assume any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed.


External Links: Some TRC Web pages may provide links to other Internet sites for the convenience of users. TRC is not responsible for the availability or content of these external sites, nor does TRC endorse, warrant, or guarantee the products, services, or information described or offered at these other Internet sites. It is the responsibility of the user to examine the copyright and licensing restrictions of linked pages and to secure all necessary permissions.


Medical Information

This website may contain general information relating to various medical conditions and their treatment. Such information is provided for informational purposes only and is not meant to be a substitute for advice provided by a doctor or other qualified healthcare professional. Patients should not use the information contained herein for diagnosing a health or fitness problem or disease. Patients should always consult with a doctor or other healthcare professional.


Contact information

TRC@chdr.nl
Teaching Resource Centre Pharmacology
Zernikedreef 10
2333 CL Leiden
The Netherlands